Factor Bioscience Spins Out A New Cell Therapy Player With Eyes On The Clinic Within 2 Years

January 6, 2021

The quest for CAR-T 2.0 is gaining an mRNA player, as Cambridge, Massachusetts-based Factor Bioscience sends a spinoff racing toward the clinic.

Factor drew the curtains on Exacis Biotherapeutics on Wednesday morning, with Sollis Therapeutics co-founder Gregory Fiore at the helm of a small immuno-oncology focused team built around Factor’s technology. The spinoff has the rights to 51 patents and just a bit of seed money from friends and family to get it going — but Fiore says an IND submission is on the horizon.